Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Daiichi Sankyo acquires U.K. rights for repaglinide, plans rebranding

Dec. 4, 2006

Pfizer stops all torcetrapib clinical trials

Dec. 4, 2006

VistaGen and Sanwa renew embryonic stem cell partnership

Dec. 4, 2006

Sirtris obtains rights to sirtuin technology from MIT

Dec. 4, 2006

TPO mimetic LGD-4665 enters phase I testing

Dec. 4, 2006

FDA Advisory Committee to discuss planned RESUS trial of Hemopure

Dec. 4, 2006

Japanese approval sought for nateglinide in combination with insulin sensitizer

Dec. 1, 2006

SB-509 begins phase II study for diabetic neuropathy

Dec. 1, 2006

Pliva receives approvals for generic Pravastatin Tablets

Nov. 30, 2006

Hematide-related peptide active in experimental pure red cell aplasia

Nov. 30, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...